http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1809297-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5517 |
| filingDate | 2005-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9701f2b556166da3c1efb0bd877d12d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d361c8cd448909c6953bdb08cd51e78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1de1ede11d052d5f921eec15214131d0 |
| publicationDate | 2007-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1809297-A1 |
| titleOfInvention | Imidazo[1,5a]triazolo[1,5d]benzodiazepine derivatives for the treatment of cognitive disorders |
| abstract | The present invention is concerned with the use of substituted imidazo [1,5-a] [1,2,4]triazolo[1,5-d] [1,4]benzodiazepine derivatives of the following formula (I); wherein R1 is halogen, lower alkyl, lower alkynyl, cycloalkyl, lower alkoxy, OCF3, -NHR, - NHC(O)R or -NHSO2R; R2 is hydrogen, methyl or aryl, which is unsubstituted or substituted by one or two substituents, selected from the group consisting of halogen or lower alkoxy; R3 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, lower alkoxy, -O(CH2)n+1-Olower alkyl, -(CH2)n-aryl, which is optionally substituted by lower alkyl or halogen, heteroaryl, -NHR, -NR2, wherein R2 may be the same or different, or is - NHCH2C=-CH, or pyrrolidin-1-one; R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, -(CH2)nO-lower alkyl, -NH-lower alkyl, cycloalkyl or aryl, n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts for the manufacture of medicaments for the treatment of cognitive enhance or for the treatment of cognitive disorders, anxiety or schizophrenia. The most preferred indication is Alzheimer's disease. |
| priorityDate | 2004-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 560.